Past HSG Research Studies and Clinical Trials
HSG is the world leader in conducting clinical studies in Huntington disease. Below are some of the more recent past studies run by the HSG.
If you are interested in taking part in a current HSG study, please visit the Current HSG Studies web page, or contact the HSG directly via phone (800) 487-7671 (toll free from the U.S. and Canada) or email (info@hsglimited.org) for more information. If you would prefer to have the HSG reach you directly about new research opportunities, please sign up to be contacted about future clinical trials and observational studies here.
Enrollment complete.
A Phase II research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will assess the safety, tolerability, and effectiveness of VX15 (a novel monoclonal antibody).
Enrollment complete.
A multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of laquininmod as treatment in patients with Huntington’s Disease.
Enrollment complete.
A randomized, double blind Phase II research study of the effects of pridopidine in patients with Huntington disease.
Enrollment complete.
A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease.
Enrollment complete.
A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease for those currently taking tetrabenazine to treat chorea and “switch” to SD-809 ER.
Enrollment complete.
Creatine Safety, Tolerability, and Efficacy in Huntington’s disease.
Enrollment complete.
Coenzyme Q10 (CoQ) in Huntington’s Disease.
In publication.
A Multi-Center, Tolerability Study of Coenzyme Q10 (UbiquinonE) in PREmanifest Huntington’s disease.
In publication.
A Multi-Center, Phase II Safety and Tolerability Trial of PBT2 in Patients with Early to Mid-stage HD.
In publication.
A Multi-Center, Study Comparing Three Doses Of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease.
Enrollment complete.
Observational Study of Neurobiological Predictors of Huntington’s Disease.